NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free AMPH Stock Alerts $40.91 +0.74 (+1.84%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$40.29▼$41.0850-Day Range$38.65▼$55.5152-Week Range$35.62▼$67.66Volume210,158 shsAverage Volume458,984 shsMarket Capitalization$2.00 billionP/E Ratio15.86Dividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amphastar Pharmaceuticals alerts: Email Address Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside61.3% Upside$66.00 Price TargetShort InterestBearish10.63% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment1.09Based on 14 Articles This WeekInsider TradingSelling Shares$660,860 Sold Last QuarterProj. Earnings Growth19.83%From $3.43 to $4.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector30th out of 910 stocksPharmaceutical Preparations Industry13th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.63% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 1.94%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 2.8 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $660,860.00 in company stock.Percentage Held by Insiders27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 19.83% in the coming year, from $3.43 to $4.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 15.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 148.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 15.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 267.25.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 0.95. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesApril 4, 2024 | insidertrades.comInsider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of StockApril 20, 2024 | americanbankingnews.comBrokers Issue Forecasts for Amphastar Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:AMPH)April 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 19, 2024 | americanbankingnews.comCapital One Financial Comments on Amphastar Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:AMPH)April 18, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy RatingApril 16, 2024 | finance.yahoo.comNaloxone Market To Reach USD 2,478.6 Million By 2032 | DataHorizzon ResearchApril 12, 2024 | finance.yahoo.comAmphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growthApril 9, 2024 | msn.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of OpportunityApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 4, 2024 | msn.comAmphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should KnowMarch 18, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)March 16, 2024 | finance.yahoo.comAMPH Apr 2024 65.000 callMarch 16, 2024 | finance.yahoo.comAMPH Apr 2024 60.000 putMarch 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 SharesMarch 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)March 6, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 SharesMarch 6, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 6, 2024 | msn.comJP Morgan Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Overweight RecommendationMarch 4, 2024 | seekingalpha.comWhy Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic AcquisitionsMarch 2, 2024 | ca.finance.yahoo.comLLY Mar 2024 980.000 callMarch 2, 2024 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Schrodinger (SDGR)February 29, 2024 | finance.yahoo.comQ4 2023 Amphastar Pharmaceuticals Inc Earnings CallFebruary 28, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year PerformanceFebruary 27, 2024 | markets.businessinsider.comHere's what Wall Street expects from Amphastar Pharmaceuticals's earningsFebruary 26, 2024 | msn.comAgios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS RatingFebruary 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)See More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$71.00 Low Stock Price Target$60.00 Potential Upside/Downside+61.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.58 Trailing P/E Ratio15.86 Forward P/E Ratio11.93 P/E Growth0.95Net Income$137.54 million Net Margins21.34% Pretax Margin26.59% Return on Equity26.95% Return on Assets12.27% Debt Debt-to-Equity Ratio0.92 Current Ratio2.17 Quick Ratio1.70 Sales & Book Value Annual Sales$644.40 million Price / Sales3.10 Cash Flow$4.47 per share Price / Cash Flow9.16 Book Value$13.35 per share Price / Book3.06Miscellaneous Outstanding Shares48,870,000Free Float35,623,000Market Cap$2.00 billion OptionableOptionable Beta0.85 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 65)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAKeros TherapeuticsNASDAQ:KROSPTC TherapeuticsNASDAQ:PTCTMaravai LifeSciencesNASDAQ:MRVIGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsNations Financial Group Inc. IA ADVBought 399 shares on 4/23/2024Ownership: 0.031%Allspring Global Investments Holdings LLCBought 24,678 shares on 4/18/2024Ownership: 0.132%Guidance Capital Inc.Bought 941 shares on 4/17/2024Ownership: 0.017%Hennion & Walsh Asset Management Inc.Sold 3,022 shares on 4/17/2024Ownership: 0.017%Bridge City Capital LLCBought 275 shares on 4/12/2024Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1 year price objectives for Amphastar Pharmaceuticals' shares. Their AMPH share price targets range from $60.00 to $71.00. On average, they anticipate the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 61.3% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2024? Amphastar Pharmaceuticals' stock was trading at $61.85 at the beginning of 2024. Since then, AMPH stock has decreased by 33.9% and is now trading at $40.91. View the best growth stocks for 2024 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by $0.03. The company had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a trailing twelve-month return on equity of 26.95%. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Janus Henderson Small Cap Growth Alpha ETF (JSML), ERShares NextGen Entrepreneurs ETF (ERSX), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), iShares U.S. Pharmaceuticals ETF (IHE) and First Trust Active Factor Small Cap ETF (AFSM). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.13%), Bridge City Capital LLC (0.07%), Nations Financial Group Inc. IA ADV (0.03%), Annex Advisory Services LLC (0.03%), Juncture Wealth Strategies LLC (0.02%) and Guidance Capital Inc. (0.02%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMPH) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.